XML 15 R5.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Operating activities:    
Net loss $ (63,012,000) $ (52,265,000)
Adjustments to reconcile net loss to net cash used for operating activities:    
Stock-based compensation expense 17,902,000 7,701,000
Depreciation and amortization 467,000 381,000
Amortization of debt discount 247,000 210,000
Realized gain on short-term investments (8,000) 0
Accretion of discount on short-term investments (1,357,000) (211,000)
Impairment on property and equipment 27,000
Loss on disposal of property and equipment 52,000
Change in operating assets and liabilities:    
Accounts receivable (9,355,000) 4,161,000
Prepaid expenses and other assets (346,000) (1,845,000)
Inventory 7,611,000 (9,508,000)
Accounts payable (6,052,000) (7,311,000)
Accrued clinical and manufacturing liabilities (868,000) (1,986,000)
Accrued payroll and employee liabilities (6,757,000) (3,612,000)
Other accrued liabilities 12,425,000 2,572,000
Net cash used for operating activities (49,024,000) (61,713,000)
Investing activities:    
Purchases of short-term investments (127,763,000) (39,388,000)
Maturities and sales of short-term investments 164,009,000
Purchases of property and equipment (2,136,000) (904,000)
Net cash provided by (used for) investing activities 34,110,000 (40,292,000)
Financing activities:    
Net proceeds from sale of common stock (205,000)
Proceeds from stock option exercises 6,539,000 4,202,000
Net cash provided by financing activities 6,539,000 3,997,000
Net decrease in cash and cash equivalents (8,375,000) (98,008,000)
Cash and cash equivalents at beginning of year 31,836,000 144,583,000
Cash and cash equivalents at end of period 23,461,000 46,575,000
Supplemental disclosure of cash flow information:    
Interest paid 500,000
Cumulative effect of adoption of new accounting standard $ 1,573,000